BREXIT MEANS WE RUN OUR OWN COUNTRY AGAIN
Summary:
As recently covered by The Spectator, a partnership on cancer treatment R&D between the UK Government and BioNTech is only possible due to the post-Brexit regulatory environment that we have been able to foster and develop – which could be of benefit not just to the UK, but to all of humanity.
Explanation:
As covered by The Spectator in early 2023, a partnership on cancer treatment R&D between the UK govt and BioNTech is only possible due to the post-Brexit regulatory environment that we have been able to foster and develop. Which could be of benefit not just to the UK, but to all of humanity. The article lays out two ways in which the BioNTech agreement demonstrates Brexit benefits:
- It allowed the UK to create a more flexible, simpler regulatory structure, and one that is better suited to ourtheir needs, and avoids the ‘if in doubt ban it’ bureaucracy that dominates the rest of Europe.
- The UK can use ithat to become a laboratory for advanced science and technology. Life sciences are the most obvious example of that, partly because the UK was already strong in that industry.
The founder of BioNTech, Ozlem Tureci, told the BBC that “we have seen in the Covid-19 pandemic with the fast approval of vaccines in the UK, that the regulatory authority is exceptional. And then there is the genomic-analysis capabilities. The UK is one of the leading nations in that regard”.
The UK taking the lead on this ground-breaking technology, is only possible due to the freedoms granted by leaving the EU.
Reference: https://www.spectator.co.uk/article/the-uk-has-finally-chalked-up-a-brexit-win/